AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 9.10
Ask: 9.66
Change: 0.38 (4.22%)
Spread: 0.56 (6.15%)
Open: 9.00
High: 9.18
Low: 9.00
Yest. Close: 9.00
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

Tue, 29th Sep 2020 18:19

Immupharma PLC - pharmaceutical company - Executes agreement to subscribe GBP250,000 for 2.6 million shares in Incanthera equal to its IPO price of 9.5 pence. Following this subscription, ImmuPharma will hold 9.9 million shares in Incanthera, representing a 15.4% stake. "ImmuPharma notes two recent positive announcements from Incanthera regarding studies of its lead product Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers," says Immupharma.

Current stock price: 11.325 pence

Year-to-date change: down 29%

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

29 Apr 21 17:33

ImmuPharma clarifies next steps for phase 3 Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.

9 Feb 21 14:13

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

9 Feb 21 10:42

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

9 Feb 21 10:36

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

24 Nov 20 21:30

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

23 Nov 20 14:29

ImmuPharma gets December date for FDA meeting

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.

20 Nov 20 12:15

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

20 Nov 20 11:04

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

10 Nov 20 17:40

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

30 Sep 20 18:37

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

29 Sep 20 18:19

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

22 Sep 20 21:17

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

11 Sep 20 14:09

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

11 Sep 20 12:17

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

2 Sep 20 11:18

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.